In the News
The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China's hot IPOs Greg Scott joined Foley's Eye on China webinar on life science innovation >>Foley webinar...
|
Tongjitang Chinese Medicines Revenues Lower in Q2
publication date: Aug 15, 2008
Tongjitang Chinese Medicines Company had the unfortunate responsibility of informing investors that, once again, its revenues for the quarter were lower than the year-earlier period. Trying to put a good face on the news, Tongjitang led its announcement by saying that Q2 revenues were up 13% from Q1, a hopeful sign. Still, the unavoidable fact remains that its Q2 sales, which came in at $17.4 million, were down 15% from 2007’s second quarter. The company’s problem remains that competitors are selling counterfeit versions of its flagship product, the TCM osteoporosis treatment Xianling Gubao. More details...
Stock Symbol: (NYSE: TCM)
|
Partner Events
BioPharm America™ 2010Boston, MA, USA September 15–17, 2010 CALAsia 2010San Diego, USA October 4-5, 2010 CHINA PRETRIALS 2010: Global Preclinical Development Summit Beijing, China October 17-19, 2010 CHINA TRIALS 2010 Beijing, China November 7-9, 2010 12th Shanghai International Forum on Biotechnology & Pharmaceutical Industry (BIO-FORUM) Beijing, China November 9-11, 2010
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|